• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention belongs to the pharmaceutical manufacturing field, which relates to a novel process for the preparation of substituted phenylacetic acids derivatives, especially relates to the preparation of 2-(4-(2-oxocyclopentyl)phenyl)propanoic acid. The process for the preparation of the precursor form of loxoprofen which use 1,4-di-halobenzylcompounds or disubstituted benzyl compounds as starting material, is through the substitution reaction of cyclopentanone groups or its precursor compounds. Wherein X is halogen, L1 is a suitable leaving group selected from halogen, OH, OMs, OTs, OTf and the like; L2 is a suitable leaving group selected from halogen, CN, OH, -CH2OH, -CHO, CH3NO2, ester group, -NR4R5, OTf, OTs, OMs, -C=CR6, -C≡CR7 and the like, wherein R4, R5, R6, R7 are short chain alkyl groups; Z is cyclopentanone group and its precursor form selected from and the like; R3 is short chain alkyl groups. L3 is a suitable leaving group selected from halogen , OH, OMs, OTs, OTf and the like, or organometallic groups. The invention also include the detailed procedure to convert the precursor compounds of cyclopentanone group to cyclopentanone, followed by the transformation of the precursor compounds of loxoprofen to loxoprofen.
    公开号:EP3680227A1
    申请号:EP18853433.3
    申请日:2018-08-07
    公开日:2020-07-15
    发明作者:Jieping LI；Zhaobo Gao；Bing CHAI；Hui Zheng；Shengmin LIU；Aqing LIU；Bibao GUO；Juncheng ZHENG；Changfa WANG；Weiwei Lu
    申请人:Jiangsu Ruike Medical Science And Technology Co Ltd；
    IPC主号:C07C255-00
    专利说明:
    [0001] This application claims priority of Chinese patent application submitted to the Chinese Patent Office on September 7, 2017, with the application number 201710800788.8 , and entitled "Preparation Method For Substituted Phenylacetic Acid Derivatives". All of its contents are incorporated in this application by reference. Field of the invention
    [0002] The invention belongs to the field of pharmaceutical manufacturingin reference to a preparation method of substituted phenylacetic acid derivatives, specifically relates to 2-(4-((2-oxocyclopentyl)methyl)phenyl)propanoic acid. Background of the invention
    [0003] Substituted phenylacetic acid derivatives are disclosed in US patents US4161538 , with good pharmaceutical activity of anti-inflammatory, analgesic and antipyretic. the structure is shown as follows:
    [0004] When A is oxygen and n=1 meanwhile and R1 is methyl group,in the above general formula structure, the representative substituted phenylacetic acid is loxoprofen. The structure is shown as follows:
    [0005] Loxoprofen is a non-steroidal anti-inflammatory type drug of with propionic acid moiety . The propionic acid derivatives drug family also include ibuprofen and naproxen et al. The loxoprofen has been launced in Brazil, Mexico and Japan in the form of sodium salt wherein hornored by Sankyo. The trade names of the loxoprofen sodium in Japan, Argentina and India are Loxonin, Oxeno and Loxomac respectively. Loxoprofen sodium is used for oral administration in these countries, and the injection administration form is approved to sell in Japan in January 2006.
    [0006] In the patent US4161538 , it disclosed the following synthetic route to prepare loxoprofen, wherein n=1, R1 represents methyl group.
    [0007] In the patent US5681979 , it disclosed the compound with the following formula:
    [0008] However, this formula was not used for the preparation of loxoprofen in this patent.
    [0009] Owing to the good medical prospects of loxoprofen sodium, it is necessary to develop more excellent process for the preparation of loxoprofen. Summary of the invention
    [0010] The present invention provides a synthetic process of substituted phenylacetic acid derivatives including loxoprofen. The novel process can synthesize the substituted phenylacetic acid and its derivaties in low-cost and high yield.
    [0011] Firstly, the present invention provides an intermediate compound of general formula G and G1:
    [0012] Secondly, The invention further provides a method for preparing general formula G and G1 compounds by the reaction of 1,4-di-halobenzyl compounds or disubstituted benzyl compounds with the precursor form of cyclopentanone group. The reaction scheme is shown as follows :
    [0013] The above formula G and formula G1 for the preparation of loxoprofen include the decarboxylation step.
    [0014] The sequence of the decarboxylation step can be the first step, the second step or the third step, which means that the sequence is changeable.And it is the best sequence that the decarboxylation ahead of the cyanation step.
    [0015] The above formula G and formula G1 for the preparation of loxoprofen include the step of transforming the precursor form of cyclopentanone group to cyclopentanone. The sequence of the transformation step can be the first step, the second step or the third step.
    [0016] The invention further provides compound of formula III, the structure is shown as follows :
    [0017] Wherein R1 is H or short chain alkyl groups; R2 is the group selected from halogen, -CN, -OH, -CH2OH, -CHO, CH3NO2, ester groups, -NR4R5, OTf, OTs, OMs, -C=CR6, -C≡CR7 and the like, wherein R4, R5, R6, R7 is alkyl groups; R3 is short chain alkyl groups.
    [0018] In above formula III, when R1 is H, R2 is halogen, the formula of the compound is shown as follows:
    [0019] The above compound of formula III-1 is prepared by the reaction of 1,4-bis(halomethyl)benzene and alkyl 2-oxocyclopentanecarboxylate, the reaction is shown as follows:
    [0020] In above formula III, when R1 is H, R2 is OH, the formula of the compound is shown as follows:
    [0021] In the above formula III, R2 can be prepared from compound of formula III-1 and compound of formula III-1'. Alternatively, treatment of 1,4- phenylenedimethanol or 1,4-bis(halomethyl)benzene with sulfonation, amination or homocoupling reaction, then proceeding substitution. Or it can be prepared by Grignard reaction, and further react with carbon dioxide. The sulfonation reaction is shown as follows:
    [0022] In above formula III, when R1 is short chain alkyl group, the formula of the compound is shown as follows:
    [0023] The above compound of formula III-3 is prepared by alkylation of formula III-2, the reaction is shown as follows:
    [0024] In addition, the above three steps such as ① substitution reaction of alkyl 2-oxocyclopentanecarboxylate, ② cyanation reaction, ③ alkylation reaction, the reaction sequence can adopt in any sequence. For example, the sequence can be ①②③, ①③②, ③②①, ②①③ or ②③①.
    [0025] When the reaction sequence is ③②①, the reaction is shown as follows:
    [0026] Wherein X is halogen, the definition of R1 and R3 are the same as above.When the reaction sequence is ②③①, the reaction is shown as follows:
    [0027] In the present invention, the substitution of alkyl 2-oxocyclopentanecarboxylate is carried out under base condition, the base is potassium carbonate, sodium carbonate, sodium alkoxide and the like.
    [0028] In the present invention, the cyanation reaction is proceeded by using common cyanating reagent, such as NaCN, KCN, CuCN2 and the like.
    [0029] In the present invention, the alkylation reaction is proceeded by using common alkylating reagent, such as dimethyl carbonate, dimethyl sulfate, trimethoxymethane, alkyl halide and the like.
    [0030] The above reaction in the invention can be carried out under the action of the organic solvent. The organic solvent may be the solvent commonly used in substitution, alkylation and cyanation reaction. The organic solvent include DMF, DMSO, NMP, 1,4-dioxane, methanol, ethanol, ethyl acetate, THF, MTBE, and acetonitrile et al.
    [0031] The intermediate compound of this invention is used for preparing loxoprofen. It is best that the compound of formula III-3 can be hydrolyzed to produce related product, the reaction is shown as follows:
    [0032] The hydrolytic reagent uses for the hydrolysis reaction is an acid commonly used in this field, which can be an organic or inorganic acid, such as sulfuric acid, hydrochloric acid or trifluoroacetic acid.
    [0033] The invention uses 1,4-bis(halomethyl)benzene compound as the starting material, and through substitution reaction, cyanation reaction and alkylation reaction in any order to produce the intermediate of formula III,
    [0034] Wherein R1 is H or short chain alkyl groups, R2 is halogen or cyano group, R3 is low-substituted alkyl groups.
    [0035] When R1 is methyl, R2 is cyano group, R3 is short chain alkyl groups, the compound of formula III-3 can be hydrolyzed to produce loxoprofen.
    [0036] The invention discloses a preparation method for loxoprofen-like compounds, including a step for conversion of a cyclopentanone group in the form of a precursor to cyclopentanone. For example, the commonly used cyclization reaction in this field is used. The precursor compound of loxoprofen is used to prepare loxoprofen compounds.
    [0037] On the other hand, the invention also provides a preparation method of loxoprofen compounds prepared by substitution reaction, decarboxylation reaction, cyanation reaction and alkylation reaction of 14-bishalomethlbenzene the reaction is shown as follows:
    [0038] Wherein X is halogen, the definition of R1 and R3 are the same as above.
    [0039] The preparation method provided by the invention has the following beneficial effects. Firstly, it provides an alternative method for preparing derivatives of substituted phenylacetic acid. Secondly, the preparation method of the invention is not reported by any prior arts. It is completely different from the compound used in the patent US5681979 . Thirdly, In the reaction process, using 1,4-bis(halomethyl)benzene as starting material is cheap and convenient. At last, The preparation method provided by the invention is suitable for industrial scale production and has certain economic benefits. Detailed Description
    [0040]
    [0041] 1,4-bis(chloromethyl)benzene (30 g, 0.17mol), DMF (150g, 4.74vol) and sodium carbonate (19.8g, 0.19mol) were added to a 250 mL round bottom flask. The reaction mixture was stirred and heated to 60 °C. Then methyl 2-oxocyclopentanecarboxylate (22.1g, 0.16mol) was added to the reaction mixture dropwise in one hour, afterwards maintain the reaction temperature for 30 minutes. Then the reaction mixture was cooled to 25 °C, filtrate and mixe the mother liquor with water. The solid is separated. The mother liquor was extracted with EtOAc. Concentrate the organic phase to give the compound of Formula 111-1(47.0 g) with a yield of 83.3% (HPLC purity of 83.3%) (wherein R1 is H, R2 is Cl, R3 is methyl).
    [0042] The compound of Formula III-1 (wherein R1 is H, R2 is Cl, R3 is methyl) (10g, 0.036mol), acetonitrile(50g, 5 vol), NaCN (1.9g, 0.039 mol) were added to a 100 mL round bottom flask. The reaction mixture was refluxed. When starting material disappeared, the reaction mixture was cooled to 25 °C. After filtration and evaporation, adding EtOAc and water while stirring. The organic layer was separated and evaporated to give the compound of Formula III-2 (9.8g) with the yield of 94.7% (HPLC purity of 93.7%) (wherein R1 is H, R2 is CN, R3 is methyl).
    [0043] The compound of Formula III-2 (wherein R1 is H, R2 is CN, R3 is methyl) (30 g, 0.11 mol), dimethyl carbonate (24.8 g, 0.28 mol), K2CO3 (1.5 g, 0.011 mol), and tetrabutylammonium bromide (1.8 g, 0.006 mol) were added to an autoclave. The reaction mixture was stirred under 130-140 °C for 10h. The pressure of the autoclave is approximately 0.3Mpa. Then the reaction mixture was cooled to 28 °C, quenched by adding small amount of benzaldehyde. Flitration and the filter cake was washed by EtOAc, 1 N HCl and water. The organic layer was separated and evaporated to give the compound of Formula III-3 (32.6g) with the yield of 80.5% (HPLC purity of 78.1%) (wherein R1 is methyl, R2 is CN, R3 is methyl).
    [0044] The compound of Formula III-3 (wherein R1 is methyl, R2 is CN, R3 is methyl) (18.5 g, 0.065 mol) and H2SO4 (80 wt.% solution in water, 16g, 0.13 mol) were added to a 100 mL round bottom flask. The reaction mixture was stirred under 80-90 °C for 5h. When the starting material disappeared, the reaction mixture was cooled to 25 °C, adding EtOAc to extract. The organic layer was washed by water and evaporated to give loxoprofen with a yield of 96.2% (HPLC purity of 93.7%).
    [0045] The compound of Formula III-1 (wherein X is Cl, R3 is methyl) (21 g, 0.075 mol), AcOH (37 mL, 2 vol) and HCl (35 wt.% solution in water, 63 mL, 3 vol) were added to a 100 mL round bottom flask. The reaction mixture was stirred under 90-95 °C for 2.5-3.5h. When starting material disappeared, the reaction mixture was cooled to 15-25 °C afterwards added water and EtOAc. The organic layer was washed with 5% NaHCO3 solution, saturated NaCl solution and water. The organic layer was separated and evaporated to give the compound of Formula IV (19.7g) with the yield of 96.1%(HPLC purity of 81.4%) (wherein X is Cl).
    [0046] The compound of of Formula IV (wherein X is Cl) (10g, 0.045mol), acetonitrile (50g, 5 vol), NaCN (2.4g, 0.049 mol) were added to a 100 mL round bottom flask. The reaction mixture was refluxed. When starting material disappeared, the reaction mixture was cooled to 25 °C. After filtration and evaporation, adding EtOAc and water to stir. The organic layer was washed by saturated NaCl solution and water; Then the organic layer was separated and evaporated to give the compound of Formula V (9.68g) with the yield of 94.7% (HPLC purity of 93.7%).
    [0047] The compound of Formula V (30 g, 0.14 mol), dimethyl carbonate (31.5 g, 0.35 mol), K2CO3 (1.5 g, 0.011 mol), and tetrabutylammonium bromide (1.8 g, 0.006 mol) were added to a 100 mL autoclave. The reaction mixture was stirred under 130-140 °C for 10h. The pressure of autoclave is approximately 0.3 Mpa. Then the reaction mixture was cooled to 28 °C, and quenched by adding small amount of benzaldehyde. Filtration and the filter cake was washed by f EtOAc, 1 N HCl and water. The organic layer was separated and evaporated to give the compound of Formula VI (31.7g) with a yield of 80.4% (HPLC purity of 81.1%) (wherein R1 is H).
    [0048] The compound of Formula VI (wherein R1 H) (18.5 g, 0.081 mol) and AcOH (37 mL, 2 vol) and HCl (35 wt.% solution in water, 55.5 mL, 3 vol) were added to a 100 mL round bottom flask. The reaction mixture was stirred under 90-95 °C for 2.5-3.5h. When starting material was disappeared, the reaction mixture was cooled to 15-25°C and was added water and EtOAc. The organic layer was washed with saturated NaCl solution and water; The organic layer was separated and evaporated to give loxoprofen (20.5 g) with the yield of 96.2% (HPLC purity of 93.7%).
    权利要求:
    Claims (14)
    [0001] A compounds of formula G and formula G1:
    [0002] A compound of formula III:
    [0003] The compound refer to claim 2 with the the formula as III-1, III-2 and III-3:
    [0004] A preparation method of formula G and formula G1 refer to claim 1. Wherein by the reaction of 1,4-di-halobenzylcompounds or disubstituted benzyl compounds with the precursor of cyclopentanone group. The reaction scheme is shown as follows:
    [0005] The preparing method refer to Claim 4. Wherein the disubstituted benzyl compounds is prepared from 1,4-di-halobenzyl compounds or 1,4-dihydroxylbenzyl alcohol. The reaction scheme is shown as follows:
    [0006] Formula G and formula G1 of claim 1. Wherein the preparation method of loxoprofen include the decarboxylation step.
    [0007] According to claim 6, the sequence of decarboxylation is from the first step to the second step and the third step.
    [0008] A preparation method of formula III-1 of claim 3. Wherein the reaction between the 1,4-bishalobenzyl compounds and alkyl 2-oxocyclopentanecarboxylate. The reaction scheme is shown as follows:
    [0009] A preparation method of formula III-2 of claim 3 is prepared by cyanation reaction with formula III-1. The reaction scheme is shown as follows:
    [0010] A preparation method of formula III-3 of claim 3 is prepared by alkylation of formula III-2. The reaction scheme is shown as follows:
    [0011] A preparation method of formula III-3 of claim 3. Wherein formula III-3 is prepared by the substitution, cyanation and alkylation reaction in any order. The reaction scheme is shown as follows:
    [0012] Role of formula III-3 in claim 3. Wherein loxoprofen and its derivatives are prepared via decaboxylation reaction and hydroxylation reaction . The reaction scheme is shown as follows:
    [0013] Role of formula G and formula G1 in claim 1. Wherein the loxoprofen or its derivatives are prepared by the conversation of precursor form of cyclopentanone group to cyclopentanone.
    [0014] A method for preparing loxoprofen or its derivatives can be proceeded by substitution, decarboxylation, cyanation, alkylation and hydroxylation reactions. The reaction scheme is shown as follows:Wherein X is halogen, R1 and R3 are short chain alkyl groups.
    类似技术:
    公开号 | 公开日 | 专利标题
    US3641127A|1972-02-08|| alkanoic acids
    AU2007282182B2|2011-09-29|A process for the preparation of optically active cyclopropylamines
    Zheng et al.2009|Phosphine-catalyzed [3+ 3] annulation reaction of modified tert-butyl allylic carbonates and substituted alkylidenemalononitriles
    JP5559066B2|2014-07-23|Process for producing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrate
    EP2049459B1|2013-10-02|Novel process for the synthesis of |-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol
    US6573404B2|2003-06-03|Method for producing ortho-alkylated benzoic acid derivatives
    KR101257217B1|2013-04-22|PROCESS OF PREPARING DERIVATIVES OF l-|-CYCLOPROPANECARBOXYLIC ACID
    CN102099343B|2014-06-04|Process for preparing 1,3-disubstituted pyrazolecarboxylic esters
    KR101148471B1|2012-05-23|Method for producing alpha-hydroxycarboxylic acids and the esters thereof
    MXPA02007987A|2005-07-25|Difluoromethylene aromatic ethers as inhibitors of glycine transport.
    KR20070067177A|2007-06-27|Process for preparing of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
    WO1994014777A1|1994-07-07|Heterocyclic carbonic acid derivatives which bind to retinoid receptors |
    HU207841B|1993-06-28|Process for producing biphenyl-carbonitrils
    EP0137242B1|1992-05-13|| phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof
    HU218488B|2000-09-28|New process for producing imidazo-pyridine derivatives
    US4327222A|1982-04-27|3,4-Diarylisoxazol-5-acetic acids and process for making same
    CA1153384A|1983-09-06|6,11-dihydrodibenz[b,e]oxepin-acetic acids andderivatives
    IL201407A|2013-01-31|1-aryl-3-sulfonyl-4,5-dihydro-1h-pyrazole-carboxylic acid and esters thereof
    JP2012107076A|2012-06-07|4-alkoxy-cyclohexane-1-amino-carboxylic acid
    RU2388753C2|2010-05-10|Method of obtaining intermediate product taking part in irbesartan synthesis
    EP2462098B1|2013-10-23|Process for the preparation of derivatives of 1-|-cyclopropanecarboxylic acid
    HU229396B1|2013-11-28|New process for the preparation of |-1-[|-alanile]octahydro-1h-indole-2-carboxy acid derivatives and their use for synthesing perindopril
    RU2553990C2|2015-06-20|Preparation of substituted 2-fluoroacrylic acid derivatives
    CH634817A5|1983-02-28|Method for producing new enolate salts.
    CH627444A5|1982-01-15|Method for producing new cyanessigsaeureanilid derivatives.
    同族专利:
    公开号 | 公开日
    JP2020532593A|2020-11-12|
    KR20200035109A|2020-04-01|
    EP3680227A4|2021-06-02|
    CN109467506A|2019-03-15|
    WO2019047654A1|2019-03-14|
    US20210078941A1|2021-03-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2019-03-16| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
    2020-06-12| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2020-06-12| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-07-15| 17P| Request for examination filed|Effective date: 20200306 |
    2020-07-15| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-07-15| AX| Request for extension of the european patent|Extension state: BA ME |
    2020-12-16| DAV| Request for validation of the european patent (deleted)|
    2020-12-16| DAX| Request for extension of the european patent (deleted)|
    2021-06-02| A4| Supplementary search report drawn up and despatched|Effective date: 20210504 |
    2021-06-02| RIC1| Information provided on ipc code assigned before grant|Ipc: C07C 51/08 20060101AFI20210426BHEP Ipc: C07C 59/86 20060101ALI20210426BHEP Ipc: C07C 45/65 20060101ALI20210426BHEP Ipc: C07C 255/41 20060101ALI20210426BHEP Ipc: C07C 253/14 20060101ALI20210426BHEP Ipc: C07C 253/30 20060101ALI20210426BHEP Ipc: C07C 255/40 20060101ALI20210426BHEP |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]